UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1 )*
BioMarin Pharmaceutical Inc. (the "Issuer")
(Name of Issuer)
Common Stock
(Title of Class of Securities)
09061G 10 1
(CUSIP Number)
Check the following box if a fee is being paid with the statement ___. (A fee is
not required only if the reporting person: (1) has a previous statement on file
reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.).
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange of 1934
("Act") or otherwise subject to the liabilities of that section of the Act but
shall be subject to all other provisions of the Act (however, see the Notes).
<PAGE>
SCHEDULE 13G
----------------------------------------
CUSIP No. 09061G 10 1
- ----------------------------------------
------------------------------------
Page 2 of 5 Pages
------------------------------------
------ ----------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Glyko Biomedical Ltd.
98-0195569
------ ----------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)
(b)
------ ----------------------------------------------------------------------
3 SEC USE ONLY
------ ----------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Canada
------ ----------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES 11,367,617 shares as of July 23, 1999
BENEFICIALLY (See Item 4(c) herein)
OWNED BY
EACH
REPORTING
PERSON
WITH
-------- --------------------------------------------------
6 SHARED VOTING POWER
0 (See Item 4(c) herein)
-------- --------------------------------------------------
7 SOLE DISPOSITIVE POWER
11,367,617 shares as of July 23, 1999
(See Item 4(c) herein)
-------- --------------------------------------------------
8 SHARED DISPOSITIVE POWER
0 (See Item 4(c) herein)
----------------- -------- --------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11,367,617
shares of Common Stock (See Item 4(c)).
------- -----------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
------- -----------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 32.6%
------- -----------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
Corporation
------- -----------------------------------------------------------------------
<PAGE>
Item 1.
(a) Name of the Issuer: BioMarin Pharmaceutical Inc. (the "Issuer")
(b) Address of the Issuer: 371 Bel Marin Keys Blvd., Suite 210
Novato, CA 94949
Item 2.
(a) Name of the Person Filing: Glyko Biomedical Ltd.
(b) Address of the Principal Office: Scotia Plaza, Suite 2100
40 King Street West
Toronto, Canada M5H 3C2
(c) Citizenship: Canada
(d) Title of Class of Securities: BioMarin Pharmaceutical Inc.
Common Stock
("Common Stock" or "Shares")
(e) CUSIP Number: 09061G 10 1
Item 3. This statement is not being filed pursuant to Rule 13d-1(b) or 13d-2(b)
Page 3 of 5
<PAGE>
Item 4. Ownership
a. Amount Beneficially Owned
At July 23, 1999, the Reporting Person may be deemed to
have beneficially owned an aggregate of 11,367,617 shares of Common
Stock. All securities as being deemed owned by the Reporting person
were purchased as follows: (a) 1,500,000 shares of Issuer's Common
Stock ($0.001 Par Value)were acquired from the Issuer in a private
placement on April 19, 1997 (b) 7,000,000 shares were issued by the
Issuer as consideration for a License Agreement dated June 26, 1997
(c)166,667 shares were acquired from the Issuer in a private placement
on June 30, 1998 (d) 2,259,039 shares issued by the Issuer as
consideration for the Issuer's acquisition of Glyko, Inc. (formerly a
wholly-owned subsidiary of the Reporting Person)(e) 441,911 shares
were issued by the Issuer for the conversion of a convertible note
plus accrued interest on July 23, 1999 and the shares were held and
included in the above aggregate ownership.
b. Percent of class
At December 31, 1999, the Reporting person may be deemed to
have beneficially owned approximately 32.6% of the outstanding
shares of Common Stock. This percentage was calculated based upon
34,832,578 shares of Common Stock outstanding as of December 31, 1999.
c. Power to vote or direct the vote and dispose or direct the
disposition of securities
At December 31, 1999, Reporting Person had the sole power to
vote or direct the vote of, and the sole power to dispose or direct
the disposition of, all 11,367,617 shares of Common Stock reported
herein to be beneficially owned by the Reporting Person. The
Reporting Person has no present intent to exercise its voting power in
a manner which would change or influence the control of the Issuer.
Page 4 of 5
<PAGE>
Item 5. Ownership of Five percent or less of a Class
Not Applicable
Item 6. Ownership of Five percent or less of a Class
Not Applicable
Item 7. Identification and Classification of the Subsidiary which Acquired the
Security being Reported on By the Parent Holding Company
Not Applicable
Item 8. Identification and Classification of Members of the Group
Not Applicable
Item 9. Notice of Dissolution of Group
Not Applicable
Item 10. Certification
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this Statement is true, complete and
correct.
Date: February 15, 2000
/s/ Raymond W. Anderson
------------------------------------------
Raymond W. Anderson
Director
Page 5 of 5
